PAL member Breast Cancer Action announced today its 6th Annual Think Before You Pink campaign. This campaign has tirelessly worked to urge consumers to ask critical questions about the hundreds of pink ribbon products and promotions that are marketed eve

The Guardian today reported on GlaxoSmithKline's (NYSE:GSK) over-the-counter weight loss drug alli ("A bitter pill for slimmers?") and its possible introduction in Europe. PAL was featured in the article, and in particular the Bitter Pill Award we gave t

Our friends at The Prescription Project have announced the launch of Postscript, their new blog on pharmaceutically-related medical conflict of interest issues: PostScript, a blog from the Prescription Project, adds another dimension to the Project’s goa

PostScript, a blog from the Prescription Project, adds another dimension to the Project’s goal of raising awareness around the medical conflict-of-interest issues that are created when drug companies open their wallets to influence prescribing. The Prescr

The New York Times ran an excellent op-ed on Sept 21, "Shy on Drugs," by Christopher Lane. Professor Lane takes psychiatrists to task for too readily diagnosing shy children as having "social anxiety disorder." He pins a chunk of the blame on the Diagno

Several PAL members are plaintiffs in class action lawsuits concerning alleged schemes by publishers of drug price data and a prescription drug wholesaler to inflate the Average Wholesales Prices of prescription drugs. Notices have been issued concerning

In June 2005 and February 2006, members of Prescription Access Litigation's coalition filed class action lawsuits against First Databank, Inc. and McKesson Corp, alleging that the companies conspired to raise drug prices by inflating the “Average Wholesal

The Attorney General of New York state and Mayor of New York City issued this announcement yesterday, of a lawsuit against Merck (NYSE:MRK): Attorney General Andrew M. Cuomo and New York City Mayor Michael Bloomberg today filed a joint lawsuit against t

In June, we reported that the Judge hearing the class action lawsuit against Abbott Laboratories for its Norvir price hike had certified the case as a nationwide class action ("Judge certifies class action in Norvir case"). Back in October 2004, PAL membe